Week 2 on semaglutide: what TikTok gets right and wrong

What's this video probably claiming?

Based on the caption and hashtags, this creator is documenting the early days of a semaglutide weight loss journey, likely sharing initial reactions, appetite changes, or early scale movement after starting the medication. Week 2 content on GLP-1 platforms almost always follows a predictable script: reduced hunger, maybe some nausea, possibly a few pounds lost, and general excitement about finally finding something that works. That narrative is relatable and gets clicks, which is why it dominates this corner of TikTok. The plus-size hashtag suggests the creator is sharing from a personal body-image angle, which adds emotional resonance but also increases the risk of overstating early results or downplaying the medical context. None of this is inherently wrong, but week 2 is genuinely too early to assess meaningful outcomes, and what feels like progress at this stage often reflects water weight shifts and caloric reduction from nausea rather than actual fat metabolism changes.

What does the science actually show?

Semaglutide works by mimicking GLP-1, a gut-derived hormone that slows gastric emptying, reduces appetite signaling in the hypothalamus, and modulates reward pathways tied to food. The clinical evidence is genuinely impressive. The STEP 1 trial (Wilding et al., 2021, NEJM) showed that adults using 2.4 mg subcutaneous semaglutide weekly lost an average of 14.9% of body weight over 68 weeks compared to 2.4% in the placebo group. That is a 68-week number, not a 2-week number. Earlier phase data from the same trial shows most patients are still in the dose-escalation period at week 2, typically starting at 0.25 mg weekly, which is a sub-therapeutic dose designed to minimize GI side effects. You are not losing meaningful fat at week 2. The SELECT trial (Lincoff et al., 2023, NEJM) further confirmed cardiovascular risk reduction in people with obesity and established cardiovascular disease, adding clinical weight to the drug's long-term value. Short-term anecdotes, however compelling, are not clinical outcomes.

Where does the social media noise diverge from clinical reality?

The gap between TikTok semaglutide content and actual clinical guidance is significant in a few specific ways. First, week 2 results are almost meaningless as predictors of long-term success. Most GI side effects, including nausea that naturally reduces caloric intake, peak in the first four to eight weeks and then subside. Creators who lose five pounds in week two and attribute it to the drug's fat-burning mechanism are almost certainly conflating nausea-driven caloric restriction with pharmacological effect. Second, the dropout and plateau reality is rarely mentioned. A 2022 analysis by Rubino et al. in Diabetes, Obesity and Metabolism showed that patients who discontinued semaglutide regained approximately two-thirds of lost weight within one year. Third, compounded semaglutide, which many TikTok users are likely using given cost and access issues, is not equivalent to FDA-approved Wegovy or Ozempic. Compounded versions vary in formulation, purity, and delivery, and no clinical trial has been conducted on compounded semaglutide specifically.

What should you actually know?

If you are considering semaglutide after watching content like this, a few things deserve your attention. The 14.9% average weight loss from STEP 1 sounds large, but it is an average across a heterogeneous population over more than a year, with consistent injection adherence and trial-level support. Real-world outcomes are typically lower. A 2023 retrospective analysis published in Obesity found that real-world weight loss with semaglutide averaged closer to 8 to 10% over 12 months. The medication also requires a clinical evaluation before prescribing, including screening for personal or family history of medullary thyroid carcinoma and multiple endocrine neoplasia syndrome type 2, both listed as contraindications in the prescribing information. Side effects beyond nausea, including pancreatitis risk and possible gallbladder disease, are underreported in short-form video content. Week 2 diary content is entertaining and sometimes genuinely supportive for people on the same path, but it should not substitute for a conversation with a licensed provider who has reviewed your full medical history.